Jornal de Assistência Farmacêutica e Farmacoeconomia (Jul 2024)

Doença Pulmonar Obstrutiva Crônica no Brasil: Análise do custo da doença

  • Suellen Mendes,
  • Wallace Entringer Bottacin,
  • Helena Hiemisch Lobo Borba,
  • Ana Carolina Melchiors

DOI
https://doi.org/10.22563/2525-7323.2024.v9.n.3.p.33-45
Journal volume & issue
Vol. 9, no. 3

Abstract

Read online

Objective: To measure the cost of Chronic Obstructive Pulmonary Disease (COPD) in Brazil to present an updated overview of the economic impact. Methods: A descriptive and retrospective analysis was carried out using macro and micro-costing techniques. It was based on information available in the Brazilian Ministry of Health’s databases, national and international guidelines for the clinical management of COPD, and the opinion of specialists. The time horizon adopted included the period from January to December 2019 and considered the direct medical costs linked to the provision of health care. Results: The analysis revealed that the costs of hospital management of COPD totaled BRL107,867,664.40. This represents 8.2% of the total costs of care related to the group of respiratory diseases in Brazil during the specified time range. In addition, it was evidenced that there is a substantial increase in the cost related to the management of the stable phase of the disease according to the severity of the condition, ranging from BRL418.50 for Stage I to BRL4,257.53 for Stage IV. Conclusion: This cost analysis and the estimated prevalence of COPD identified in Brazil demonstrate the importance of implementing effective strategies and public policies aiming to reduce risk factors associated with the disease.

Keywords